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Abstract
Acinetobacter  baumannii has  emerged  as  a  major  nosocomial  pathogen.  Meropenem  and 
imipenem  are  the  most  commonly  used  antimicrobials  to  treat  infections  inflicted  by  this 
pathogen. Recently, resistance mechanisms have evolved causing this microorganism to become 
resistant to these antibiotics.  
Eighty five clinical isolates of A. baumannii were collected from inpatients at Makassed Islamic 
Hospital  in  Jerusalem,  Palestine.  Antimicrobial  susceptibility  testing  was  performed  against 
several  antibiotics  including  meropenem,  ciproxin  and  colistin.  Minimal  Inhibitory 
Concentration was performed on these three  antibiotics  individually and on meropenem and 
ciproxin in combination. Polymerase chain reaction was performed to detect mutations in the 
Quinolone Resistant Determining Region for  selection gyrA and  parC genes. In addition, PCR 
was performed to detect the acquisition of beta lactam class D oxacillinase genes, specifically 
oxa24, oxa23, oxa51 and oxa58. Representative samples were sequenced to confirm the presence 
of mutations responsible for quinolone resistance and the presence of beta lactam oxacillinase 
genes responsible for carbamepenem-resistance. 
The results obtained revealed that  A. baumannii was resistant to ciproxin (86%), meropenem 
(74%) and none was resistant to colistin. Combination results revealed the existence of synergy 
between ciproxin and imipenem where the MICs were elevated in both (9.5%).  Partial synergy 
was seen in situations when the organism was resistant to both drugs with the MIC elevated for 
one of the two drugs tested (52%).  
Our results indicated the presence of correlation between resistance to ciproxin and mutations on 
gyrA at codon 83  for all isolates with MIC ≥2 μg/ml.  Sequencing revealed the presence of 
substitution of serine to leucine. Mutations in the  parC gene were detected on codon 80 only 
when the MICs were > 32 ug/ml. 
Among the  A. baumannii resistant isolates to meropenem, our results revealed that all isolates 
carried oxa51, 86.7% carried oxa24 while only 3.3% carried by each of oxa23 and oxa58 genes. 
 Regarding gyrA and parC, our results agree with published literature as in many other countries. 
Regarding  beta  lactamase  genes,  the  rate  of  oxa24  carriage  seems  to  be  similar  to  results 
obtained  by other  Mediterranean  and European  countries  such  Spain  and  Portugal.  A small 
number of isolates carried the other clusters of beta lactamases pointing to the potential of further 
spread of these genes.  
The  aim  of  this  project  was  to  investigate  the  antimicrobial  susceptibility  pattern  of  A. 
baumannii and  to  determine  the  presence  of  synergistic  effects  between  meropenem  and 
ciproxin. In addition, we investigate the presence of mutations on the  gyrA and  parC genes, 
responsible for quinolone resistance, and the acquisition of beta lactamase genes oxa51, oxa24, 
oxa23 and oxa51 responsible for carbapenem resistance.  
الخلصة
 تعتبر بكتيريا السينيتوباكتر بومانيي من أهم الجراثيم المسببة للمراض المعدية في المستشفيات.اكثر  المضادات الحيوية
 المستخدمة لعلج العدوى الناتجة عن هذه البكتيريا هما ميروبينيم و اميبنيم . ولقد نشأت طرق تسببت في مقاومة هذه البكتيريا
 .للمضادات الحيوية
  عينة من المرضى المقيمين في مستشفى المقاصد الخيرية السلمية  في مدينة القدس في فلسطين. تم فحص58لقد تم جمع 
 يمنع )CIM( استجابة هذه الجراثيم لعدة مضادات حيوية منها ميروبينيم، سيبروكسين وكوليستين. وكذلك تم تقدير اقل تركيز
 لتحديد RCP نمو هذه الجرثومة باستخدام المضادات الحيوية النفة الذكر فرادى وميروبينيم والسيبروكسين معا. عمل فحص
 عمل RCP ، بالضافة .Crap dna Aryg الطفرات الوراثية الموجودة على منطقة تحديد المقاومة للكوينيلونز لجينات
 اختيرت بعض ..85axo dna 15axo ,32axo ,42axO  اوكسيلينيز وتحديدا D لتحديد اكتساب جين بيتا لكتام من صنف
 للتأكد من وجود طفرات مسببة لمقاومة هذه البكتيريا للكوينيلونز واكتساب جينات بيتا لكتام AND  العينات لتحديد سلسلة
. المذكورة المسؤولة عن المقاومة للكارباميبينيم
  % للميروبينيم وعدم وجود أي مقامة47% من هذه الجرثومة مقاومة للسيبروكسين، 68أظهرت نتائج هذه الدراسة بأن 
 مرتفع CIM  % في حالت وجود5.9للكوليستين.   كما أظهرت النتائج وجود تعاون كلي بين الميروبينيم والسيبروكسين في 
 لحدهما. CIM  % عند وجود مقاومة لكل المضادين الحيويين مع ارتفاع25لكل المضادين الحيويين وتعاون جزئي بنسبة 
  لجميع الجراثيم المعزولة38على كودون  Aryg  كما تبين وجود علقة بين المقاومة للسيبروكسين ووجود طفرة على جين
 تحديد مكونات السلسلة المينية لهذا الجين، تبين وجود احلل للحامض الميني سيرين للوسين. . lm/gμ 2≥ CIM ولها
 . lm/gμ 23≥ CIM  لجميع الجراثيم المعزولة ولها08فالطفرة كانت موجودة على الكودون   Crap بالنسبة لجين ال
  %، جين001جين بنسبة  15axo من بين بكتيريا السينيتوباكتر بومانيي المقاومة للميروبينيم، أسفرت نتائجنا عن وجود
   .85axo و  32axo  % لكل من3.3% ونسبة 7.68بنسبة  42axo
 توافقت نتائجنا مع الدراسات العالمية. أما بالنسبة للنتائج لجينات البيتا لكتاميز، فتبين ان هذه ، Crap و  Aryg  بالنسبة   ل
 تماثل نتائج الدراسات المعمولة في اسبانيا والبرتغا ل.  وجود عدد قليل من 42axo النتائج للجين المسؤول عن المقاومة وهو
 .الجراثيم المعزولة والتي تحمل جينات بيتا لكتاميز اخرى يؤكد على احتمالية انتشارها في منطقتنا
  بكتيريا السينيتوباكتر بومانيي ووجود فعالية تعاون بين المضادين الحيويينالهدف من هذه  الدراسة هو تحديد مدى مقاومة   
 المسؤولة عن مقاومة هذه الجرثومة للكوينيلونز واكتشاف Crap و Aryg ميروبينيم و سيبروكسين مع تحديد الطفرات لجينات
 المسؤولة عن عدم استجابة هذه 85axo  و 32axo ، 42axo ، 15axo احتمال اكتساب احد جينات البيتا لكتاميز مثل
.الجرثومة للكارباميبينمز
1Description of Makassed Islamic Charitable Hospital
Makassed Islamic Charitable Society was officially established in 1956. It is a 
Palestinian non-profit, non-governmental organization that provides diversified 
human services and extends its services in accordance with its laws, without 
discrimination of religion, gender, color, creed, or political affiliations. In 1964, the 
society built its hospital on the Mount of Olives in Jerusalem. The hospital was 
officially inaugurated in 1968 as a small community hospital with few departments 
and a limited number of beds.
Makassed hospital now is a leading medical center in Palestine providing secondary 
and tertiary health for the population; it provides services to patients from all over 
Palestine. Makassed Hospital has the capacity of 250 beds, staffed by 560 employees. 
Makassed hospital consists of 10 main departments: Surgical department (general and 
Laparoscopic Surgery, Neurosurgery, Vascular, Thoracic, Open Heart, Plastic, 
Maxillofacial, Orthopedics, Urology, and Pediatric Surgery), Internal Medicine and 
Cardiology, Pediatric department, Gynecology department, Anesthesia department, 
Neonatal department, Emergency department, Genetics department and Radiology 
department. It also consists of supportive services in Outpatient clinics, central Blood 
Bank, and General Hospital Laboratory (provides variety of routine and specialized 
tests with strict internal and external quality control measures).
Makassed Hospital has its own nursing School, and has a residency program in many 
specialties, and it is active in both clinical and basic sciences research.
The annual number of admissions ranges between 10000 to 11000, the outpatient 
visits between 34000 to 37000, the Emergency visits between 15000 to 17000, the 
surgical operations between 3500 to 4500.
2Introduction
Acinetobacter Spp.:
The current genus designation, Acinetobacter (Greek, akinetos, or  nonmotile), was 
initially proposed by Brisou and Pre´vot in 1954 to separate the nonmotile 
microorganisms from the motile ones within the genus Achromobacter (1). It was not 
until 1968 that this genus designation became widely accepted (2). The genus 
Acinetobacter, as currently defined, comprises Gram-negative, strictly aerobic, 
nonfermenting, nonfastidious, nonmotile, catalase-positive, oxidase-negative bacteria 
with a DNA G+C content of 39% to 47%. Based on more recent taxonomic data, it 
was proposed that members of the genus Acinetobacter should be classified in the 
new family Moraxellaceae within the order Gammaproteobacteria, which includes the 
genera Moraxella, Acinetobacter, Psychrobacter, and related organisms (3).
The genus Acinetobacter is commonly found in soil and water, it can also be found on 
the skin of healthy people especially healthcare workers. All types or species of 
Acinetobacter can cause human disease, mainly A. baumannii which accounts for 
about 80% of reported infections. This genus consists of at least 12 DNA 
hybridization groups referred to as genospecies. The individual genospecies are 
classified as follows:
Genospecies 1, the type species for A. calcoaceticus which isolated principally from 
soil. 
Genospecies 2, for A. baumannii which includes all isolates previously referred to as 
A. calcoaceticus var. anitratus, it is the most prevalent species isolated from human 
clinical specimens.
3Genospecies 4 is named A. haemolyticus.
Genospecies 5 is named A. jinii.
Genospecies 7 is named A. johnsonii.
Genospicies 8 is named A. lwoffii.
Genospecies 3, 6, 9, 10, 11, and 12 are unnamed.(4 , 5)
Acinetobacter cells are short, gram-negative rods, measuring 1-1.5 by 1.5-2.5 microns 
during growth; they often become more coccoid during stationary phase. Cells are 
pleomorphic aerobic found in pairs or small clusters of coccobacilli  by Gram’s 
staining similar to H. influenzae as shown in Figure 1B. The organism has a tendency 
to retain crystal violet leading to incorrect identification as gram-positive cocci 
particularly in older cultures. Most strains grow well on nonselective agar forming 
smooth pale colonies as shown in Figure 1A. On MacConkey agar, the colonies are 
faint with blue tint while forming deeper cornflower blue color on eosin methylene 
blue agar (5).
                 Figure 1A.                                                                Figure 1B
A. Morphological appearance of A. baumannii on blood agar plates.
B. Gram staining of a colony taken from the agar plate (4).
4 Acinetobacter are non fermenters utilizing a wide variety of carbon and other energy 
sources. The organism can survive for months on clothing and bed sheets, bed rails, 
ventilators and other surfaces including sinks and doorknobs, making nosocomial 
transmission extremely difficult to control.
 A. baumannii does not have fastidious growth requirements. It grows at various 
temperatures and pH levels. This versatile organism exploits a variety of both carbon 
and energy sources. These properties explain the ability of Acinetobacter species to 
persist in either moist or dry conditions in the hospital environment, thereby 
contributing to its transmission and spread. This hardiness combined with its intrinsic 
resistance to many antimicrobial agents, contribute to the organism's fitness and 
ability to spread in the hospital setting (6).
Features present on the outer cell membrane in gram negative bacteria such as porins 
and efflux channels contribute to antibiotic resistance. Porins are protein channels that 
allow the transport of molecules across the outer cell membrane and serve as 
attachment sites for antibiotics. However, A. baumannii has fewer and smaller porins 
than other Gram-negative bacteria, thereby decreasing cell permeability and 
increasing antibiotic resistance. (7)
Infections Caused by A. baumannii 
Acinetobacter baumannii (formerly A. calcoaceticus var. anitratus ) is a major cause 
of nosocomial infections and  the second most frequent non-fermenter encountered in 
clinical laboratories . The sources of A. baumannii include soil and foods, it colonizes 
the skin of healthy humans in low density for a short time. The nature of the organism 
and its durability as well as its resistance to antibiotics makes it a successful infectious 
5agent in hospitals. Infections with A. baumannii most often occur in critically ill 
hospitalized patients, mainly in advanced age, immunosuppression and burn injuries. 
It has been well recognized as a potentially resistant organism, particularly in 
nosocomial infections. Its resistance pattern usually includes many commonly used 
antimicrobial agents such as penicillins, cephalosporins, monobactams, 
aminoglycosides, and fluoroquinolones. Carbapenems (imipenem and meropenem) 
have often become the drugs of choice for treatment of infections caused by this 
organism. Carbapenem–resistant Acinetobacter has been increasingly reported. 
Resistance to the carbapenem class of antibiotics makes infections caused by 
multidrug- resistant Acinetobacter difficult if not impossible to treat. The different 
infections caused by this organism are summarized below: 
Pneumonia: The infection occurs most commonly during the rainy season in people 
with a history of alcohol abuse, the elderly and inpatients on respirators. Pneumonia is 
a major cause of death in hospitalized patients with chronic obstructive pulmonary 
diseases and the elderly. Large surveillance studies from the United States revealed 
that 5 to 10% of cases in the ICU are prone to contract pneumonia due to A. 
baumannii (8). Although Community-acquired pneumonia due to A. baumannii has 
worldwide distribution, it is more prevalent in the tropical regions of Australia and 
Asia (9, 10, 11, 12, and 13). 
Septicemia:  Although  A. baumannii   is the major cause of ICU-acquired 
bloodstream infections, it is less common in non-ICU  wards. The infection is 
probably associated with catheters. Septicemia ranks as the third highest crude 
mortality rate in the ICU, exceeded only by infections caused by P. aeruginosa and 
Candida albicans (14).
6Wounds  :   wound infections usually include burns, wounds inflicted during combat in 
wars such as that acquired by American soldiers in Iraq and from natural disasters 
such as hurricanes and earthquakes. This organism caused a percentage of 2.1% of 
ICU-acquired skin/soft tissue infections (8). A. baumannii is a well-recognized 
pathogen in burn units that may be difficult to eradicate (15). Reports indicated a high 
frequency of wound infections caused by A. baumannii was detected in American 
soldiers fighting in Iraq or Afghanistan (16,17).
Urinary Tract Infections  :   These type of infections are commonly encountered in 
patients with catheters colonized by  A. baumannii. It is not common for this organism 
to cause UTI in healthy outpatients.
The ability of this organism to cause rare infections such as meningitis subsequent to 
post-neurosurgical procedures is reported. Patients who developed meningitis had 
usually undergone neurosurgery and had external ventricular drain (18). 
Risk factors for acquiring Acinetobacter baumannii 
There are many factors that predispose infections with A. baumannii. These factors 
include advanced age, antimicrobial therapy within the past 90 days, evidence of 
high-frequency antibiotic resistance in the community or hospital, severe 
immunosuppression due to certain diseases or chemotherapy, multiple co-morbid 
conditions and prolonged hospitalization (especially critical care) or residence in an 
extended care facility. Use of artificial medical devices may also contribute to 
contracting infections by this organism. Some of these medical devices are:  dialysis, 
mechanical ventilators, sutures and catheters (central venous, intravenous and 
urinary). 
7Pregnant healthcare workers are not at increased risk of becoming infected with this 
organism, and can therefore care  for patients infected or colonized with this 
organism.
Sources of Acinetobacter baumannii Transmission in 
Hospitals 
  
Supplies: Supplies are an important environmental source of this organism. These 
supplies include crash carts, weighing hammocks, protective masks, shared 
equipment, invasive equipment and interventions, catheters (ie, central lines, urinary) 
and administration of medications from multidose vials. 
Room variables: Room environment is another important source of A. baumannii. 
Many objects present in hospital rooms may be shared by patients and the 
medical staff who in turn may spread this durable organism to other patients. 
Such objects include bed rails, blood pressure cuffs, furniture, door knobs or 
handles, intravenous stands, linens, foam mattresses, paper towel dispensers, 
pillows, containers for sharp objects-disposal, sinks, table tops, mechanical 
equipment, air conditions, hemodialysis machinery, infusion pumps, key panels 
of monitors, computers, continuous venous hemodialysis machines, mattresses 
with pneumatic pumps, ventilators and  respiratory equipment.
Liquids: Body fluids may be considered as a significant source of A. baumannii. 
Examples of body fluids and other related liquids and fluids include body fluids 
such as blood products, and other fluids that are commonly used in the hospital 
and usually introduced intravenously such as normal saline and enteral formulas 
8as well as other miscellaneous fluids such as  soaps, detergents and  non-sterile 
distilled water placed in humidifiers.
Epidemiology:
A. baumannii is primarily a healthcare-associated pathogen. It is increasingly reported 
as the cause of outbreaks and nosocomial infections such as blood-stream infections, 
ventilator-associated pneumonia, urinary tract infections and wound infections. 
Acinetobacter isolates demonstrate increasing resistance to commonly prescribed 
antimicrobials. Multidrug-resistant A. baumannii has been reported worldwide and is 
now recognized as one of the most difficult healthcare-associated infections to control 
and treat.
Multidrug-resistant (MDR) Acinetobacter rarely causes serious infection in healthy 
people. Sources of outbreaks are frequently detected in intensive-care and burn units 
involving patients on mechanical ventilators. Transmission of A. baumannii during 
outbreak setting primarily involve respiratory equipment such as resuscitator bags, 
valves, ventilator circuits, spirometers, peak flow meters and suction catheters. Other 
sources of transmission may include humidifiers, warming baths, multidose vials, 
distilled water, pillows, mattresses, bedpans, showers and faucets. In 50% of reported 
outbreaks caused by A. baumannii, the source of transmission was not identified. 
An outbreak of MDR  Acinetobacter at Johns Hopkins Hospital was linked to the use 
of a pulsatile lavage with suction device used to care for wounds. Widespread 
environmental contamination and healthcare-associated transmission of the organism 
occurred during this outbreak. As a result, the Hospital Epidemiology and Infection 
9Control Department has implemented new infection control precautions for all 
treatments involving pulsatile lavage suction (19).
Antimicrobial susceptibility:
Minimum Inhibitory Concentrations (MIC) is defined as the lowest concentration of 
an antimicrobial that inhibits the growth of a microorganism after overnight 
incubation. Minimum Bactericidal Concentrations (MBC) is defined as the lowest 
concentration of an antimicrobial that kills 99% of the microorganism when the MIC 
tube or two dilutions above the MIC is plated on agar media. Antimicrobial 
susceptibility can be performed by several methods using standardized procedures 
according to the CLSI. Some of these methods include:
Reference methods: Agar dilution, broth dilution (Macro and micro) and disk 
diffusion by the Kirby-Bauer method. 
Commercial methods : Manually performed, E-test and dry-form broth microdilution 
( long-shelf life ), Automated, Micro Scan, Vitek and Vitek2.
Agar dilution susceptibility testing is the solid equivalent of broth dilution 
susceptibility testing, either in macro- or micro broth format. The advantage of using 
the agar dilution method over broth-based dilution methods is that it allows the 
simultaneous testing of a large number of strains on a single agar plate. A total 
number of 32 to 37 can be usually placed on one 90 mm agar plate containing a 
specific concentration of the antibiotic to be tested.  Steers-Foltz or a similar 
replicator (Figure 2)  is used in this procedure. This method is therefore well suited 
for the rapid evaluation of new antibiotics or related compounds for large-scale 
testing.  
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 Disadvantages of this method include the incorporation of an additional variable 
(agar), in the medium. In addition, the shelf life of these prepared agar plates is 
limited owing to dehydration and degradation of the added antimicrobial agents  (20).
                                       Figure 2. Steer’s Replicator
A susceptible result implies that an infection due to the isolate may be appropriately 
treated with the proper dosage of an antimicrobial agent recommended for this type of 
infection. A resistant result implies that the isolate is not inhibited by the tested 
antibiotic indicating the evolution of resistance which may warrant further evaluation. 
Alternative therapeutic agents must be used for successful treatment of this infection. 
An intermediate result implies that an infection caused by the isolate may be properly 
treated by increasing the dosage of the antibiotic to achieve higher concentrations at 
the infected body site. The category intermediate, constitutes a safety margin or a 
buffer zone‌ to identify the presence of small, uncontrolled technical factors from 
causing major discrepancies in interpretations (21). 
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Combination Therapy
Combination therapy using two or more antibiotics is primarily used to prevent the 
emergence of resistant strains. It is also used to treat life threatening infections when 
the etiological agent is not known yet. In addition, it is essential to use combination 
therapy to reduce the dosage and avoid the toxic effects of antibiotics as well as to 
reduce the selection pressure causing the emergence of resistant strains (Figure 3).
  Figure 3. Selection pressure for antimicrobial resistant strains.                     
12
 Synergy occurs when the effects of combined antibiotics is greater than the sum of 
the effects of the individual ones. Antagonism occurs when one antibiotic, usually the 
one with the least effect, interferes with the effects of another antibiotic. Many 
combinations have been evaluated using in-vitro techniques and animal models 
(22,23 and 24) including various combinations of quinolones, β-lactams, and/or 
amino glycosides. Quinolone combination tests using a mouse-pneumonia model, 
where ciproxin and/or levofloxacin, is combined with imipenem or amikacin gave 
reduced efficacy with  a lack of enhanced activity in A. baumannii infected mice (25). 
Interestingly, enhanced activity was seen when aztreonam was tested in combination 
with other β-lactams against a selected group of Metallo β-lactamase (MBL) 
producing A. baumannii strains (26). Using a mouse pneumonia model, Montero et al. 
reported on the potential efficacy of imipenem and rifampin against a carbapenem-
resistant and rifampin-resistant A .baumannii strain (27). 
 
Mechanisms of Resistance:
To understand the mechanisms of bacterial resistance, it is necessary to understand 
bacterial physiology, the pharmacology of antimicrobial drugs, and the molecular 
biology of infectious agents. The genes responsible for resistance mechanisms may be 
located either on the chromosome or on extra-chromosomal elements such as 
plasmids. Plasmids are circular pieces of DNA that replicate autonomously and 
independently of the chromosome. The practical significance of the difference is that 
the chromosomal DNA is relatively stable whereas the plasmid DNA is easily 
mobilized from one strain to another. In addition, the linking of resistance genes for 
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multiple antibiotics on a plasmid allows transfer of resistance to newly characterized 
resistant organisms.
The most common mechanism for transferring resistant genes is conjugation. An 
additional genetic transfer factor is necessary before a plasmid that carries a resistant 
gene can move from one organism to another. Recently, transposon (transposable 
genetic element) is considered the most delineated transfer mechanism. Transposons 
can carry portions of plasmids and more importantly, they can carry a piece of the 
chromosome from one bacterium to another by conjugal transfer (conjugative 
transposon or jumping gene).
Resistance can be caused by several  mechanisms (4):
• The presence of an enzyme that inactivates the antimicrobial agent.
• The presence of an alternative enzyme that replaces the enzyme inhibited 
by the antimicrobial agent.
• A mutation in the antimicrobial agent’s target producing an altered, which 
reduces the binding of the antimicrobial agent.
• Posttranscriptional or posttranslational modification of the antimicrobial 
agent’s target, which reduces binding of the antimicrobial agent.
• Reduced uptake of the antimicrobial agent due to influx associated 
problems.. 
• Active efflux of the antimicrobial agent. 
• Overproduction of the target of the antimicrobial agent. 
Other mechanisms of resistance to antibiotics may still  be unrecognized. 
On the other hand, a gene which is not expressed in vitro may be expressed in vivo. 
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A resistance mechanism may be expressed continuously whether an inciting challenge 
is present or not. This is referred to as constitutive expression. In contrast, some genes 
must be induced to produce their product after exposure to the challenge substance. 
Most of the enzymes of gram- negative bacteria are cell bounded so that they exert 
their effects only if the antibiotic enters the bacterial cell (28). 
Antibiotic resistant genes in MDR Acinetobacter  baumannii
CARBAPENEM:  
Mode of action: It inhibits bacterial cell wall synthesis similar to other beta-lactam 
antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by 
beta-lactamases or cephalosporinases (Figure 4).
. 
                                  Figure 4. Structure of carbapenem backbone
Resistance to carbabenems:
 Resistance generally arises due to mutations in penicillin binding proteins, production 
of metallo-beta-lactamases, or resistance to diffusion across the bacterial outer 
membrane.   
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Of the β-lactamases, the carbapenemases are the most prevalent. These include  the 
serine oxacillinases (Ambler class D OXA type) and the metallo-lactamases (MBLs) 
(Ambler class B) (29, 30 and 31). Thus far, the Ambler class A  carbapenemases 
(KPC, GES, SME, NMC, and IMI) have not been described for A. baumannii (30). 
MBLs are being less commonly identified in A. baumannii than the OXA-type 
carbapenemases. The hydrolytic activities of OXA-type toward carbapenems are 
significantly more potent (100- to1,000-fold) (29). These enzymes have the capability 
of hydrolyzing all β-lactams (including carbapenems) except the  monobactam 
aztreonam, which may assist in laboratory detection of resistant strains. Of the five 
MBL groups described to date, only three have been identified in A. baumannii, 
including IMP ,VIM, and SIM  types (31),
Four groups of carbapenem-hydrolyzing oxacillinases have been described in A. 
baumannii: 
The first group consists of OXA-23, OXA-27 and OXA-49 which have 99% amino 
acid homology. The gene encoding for this group is known as bla OXA-23 (32).
The second group consists of OXA-24, OXA-25, OXA-26, and OXA-40. This 
group shares 60% homology with the first group. Variations among these enzymes 
are due to few amino acid substitutions. The gene encoding for this group is known 
as bla OXA-40. (32 and 33). 
The third group consists of B-lactamase OXA-51, which shares less than 63% 
amino acid homology with the other two groups. OXA-51 has been recently 
identified in A. baumannii isolates from Argentina and not associated with 
resistancy. The gene encoding for this group is known as bla OXA-
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 The fourth group consists of the most recently discovered enzyme OXA-58, which 
is less common and associated with resistancy.  The gene encoding for this        group 
is known as bla OXA-58. (32 and 34).
The first description of an OXA carbapenemase in A. baumannii was OXA-23. 
It was detected in a clinical isolate in Scotland in 1985 before the introduction of 
carbapenems. Since then, this plasmid-encoded enzyme, initially named ARI-1 
(acinetobacter resistant to imipenem) has been also discovered in England, Brazil, 
Polynesia, Singapore, Korea, and China (35 and 36). OXA-24-like enzymes were 
detected in isolates epidemiologically linked to Spain and Portugal since 1996 (37, 
38). OXA-51 and OXA-58 were the most recent discoveries. The first known OXA-
58-producing Acinetobacter isolate was collected in France in 2003 (39). 
Subsequently, this enzyme was found in an outbreak-strain in a French hospital (40) 
and in isolates from several southern and eastern European countries. A plasmid-
borne OXA-58 carbapenemase, was found in strains isolated in England, Argentina, 
Spain, Turkey, Romania, Austria, Greece, Scotland, and Kuwait ( 41,42 ). 
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Figure 5. Countries that have reported an outbreak of carbapenem-resistant 
Acinetobacter baumannii. Red signifies outbreaks reported before 2006, and yellow 
signifies outbreaks reported since 2006 (51).
FLUOROQUINOLONES
Mode of action: Quinolones bind to the A subunit of DNA gyrase (topoisomerase) 
and prevent supercoiling of DNA, thereby inhibiting DNA synthesis. 
Fluoroquinolones  (Figure 6) exert their antibacterial effects by inhibition of certain 
bacterial topoisomerase enzymes, namely, DNA gyrase (bacterial topoisomerase II) 
and topoisomerase IV. These essential bacterial enzymes alter the topology of double-
stranded DNA (dsDNA) within the cell. DNA gyrase and topoisomerase IV are 
heterotetrameric proteins composed of two subunits, designated A and B. The genes 
encoding the two A and two B subunits are referred to as gyrA and gyrB (DNA 
gyrase) or parC and parE (DNA topoisomerase IV). DNA gyrase is the only enzyme 
that can affect supercoiling of DNA (28).  Inhibition of this activity by 
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fluoroquinolones is associated with rapid killing of the bacterial cell. Topoisomerase 
IV can also modify the topology of dsDNA. While DNA gyrase seems to be important 
for maintenance of supercoiling, topoisomerase IV is predominantly responsible for 
the separation of daughter DNA strands during cell division (43).  
                             Figure 6. Structure of quinolone backbone
 Resistance to Fluoroquinolones:
There is a region in the genes responsible for quinolone resistance known as 
Quinolone Resistance Determining Region (QRDR). The mutations that play the most 
important role in the acquisition of resistance to quinolones located in the QRDR 
occur on the gyrA and parC genes. Mutations affecting the QRDR of the gyrB gene 
seem to be more frequent in quinolone-resistant strains obtained in vitro than in 
clinical isolates. Mutations affecting the parE gene are extremely unusual among 
clinical isolates of Gram-negative bacteria. Many studies were conducted on A. 
baumannii to investigate mutations that occur in QRDR,  specifically in ParC and 
gyrA. These studies were done in Spain, France, USA, UK and Israel (44 and 45) 
Variable results were obtained from these studies, but all confirmed the presence of 
mutations in gyrA resulting in resistance to quinolones regardless of the MIC levels. 
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Double mutations in gyrA and parC genes correlated with elevated MICs. It has been 
found that the amino acid residues most frequently mutated in gyrA occur at serine 83 
and glycine 84, these are the hotspots for mutation associated with resistance to 
ciprofloxacin. The hotspots for mutations in parC genes occur at serine 80 and 
glutamate 84. Mutations at other sites of ParC were identified in other studies but 
with less frequency (44.45 and 46).
  
 AMINOGLYCOSIDES
Mode of action: The aminoglycosides irreversibly bind to the 30S ribosomes and 
freeze the 30S initiation complex (30S-mRNA-tRNA), inhibiting the initiation of 
protein synthesis. In addition, aminoglycosides can also slow down protein synthesis 
during the occurrence of initiation inducing misreading of the mRNA. 
Aminoglycosides ( Figure 7)  such as gentamicin, tobramycin, amikacin, and 
streptomycin are commonly used antimicrobial agents in the treatment of infections 
caused by both gram-negative and gram positive organisms.
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                               Figure 7. Structure of aminoglycoside backbone
Resistance to aminoglycosides:
Resistance to these antimicrobial agents is widespread. More than 50 aminoglycoside-
modifying enzymes are already described. The genes encoding for these modifying 
enzymes are associated with gram-negative bacteria. Depending on the type of 
modification, these enzymes are classified as aminoglycoside acetyltransferases 
(AAC), aminoglycoside adenylyltransferases also named aminoglycoside 
nucleotidyltransferases (ANT), and aminoglycoside phosphotransferases (APH). The 
position of the modification on the substrate is denoted by a number with or without a 
prime or double prime.  Sub-classification of these enzymes depends on the 
aminoglycoside substrates that are modified. The gene designations follow this 
pattern, but a further sub-classification is made when different genes encode enzymes 
that have the same substrate profile. Aminoglycosides modified at amino groups by 
AAC enzymes or at hydroxyl groups by ANT or APH enzymes loose their ribosome-
binding ability and thus no longer inhibit protein synthesis (47).
In addition to aminoglycoside-modifying enzymes, efflux systems and rRNA 
mutations have also been described to play a role in the organism’s resistance to this 
type of antimicrobial agents (48). The enzymes that are most commonly responsible 
for resistance in microorganisms to aminoglycosides include Phosphotransferase gene 
(alpha A6), adenylyltransferase genes (aadA1 and aadB) and acetyltransferase genes 
(aacC1 and aacC2) (49). 
 CEPHALOSPORINS
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Mode of action  :  Similar to other beta-lactam antibiotics, (Figure 8) such as 
penicillins, cephalosporins have the same bactericidal mode of action. Cephalosporins 
disrupt the synthesis of the peptidoglycan layer in the bacterial cell walls. The 
peptidoglycan layer is responsible for cell wall structural integrity. The final step in 
the synthesis of the peptidoglycan layer, transpeptidation, is facilitated by 
transpeptidase enzymes known as Penicillin Binding Proteins (PBPs). PBPs bind to 
the terminal D-Ala-D-Ala at the end of peptide chain (peptidoglycan precursors) to 
crosslink the peptidoglycan layers together. Beta-lactam antibiotics have structural 
similarity to the D-ALA-D-Ala terminal end of the peptide chain normally present in 
the peptidoglycan component of the bacterial cell wall. Therefore, they compete with 
the PBPs to bind to this site, thus disrupting the formation of the peptidoglycan layer 
in the bacterial cell wall.  
                          Figure 8. Strucure of Cephalosporin backbone
Resistance to cephalosporin  s  : The most prevalent mechanism of resistance in A. 
baumannii to β- lactam antibiotics is mediated by the enzymatic degradation of the 
beta-lactam ring by β-lactamases. However, in keeping with the complex nature of 
this organism, multiple mechanisms of resistance may often work in concert to 
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produce the same resistant phenotype. Inherent to all A. baumannii strains are 
chromosomally encoded AmpC  cephalosporinases, also known as Acinetobacter-
derived cephalosporinases (ADCs) (50). Over expression of these enzymes in A. 
baumannii is regulated by a key determinant, an upstream IS element known as 
ISAba1. The presence of this element highly correlates with increased AmpC gene 
expression and resistance to extended-spectrum cephalosporins. Cefepime and 
carbapenems appear to be stable in response to these enzymes.
Extended-spectrum β-lactamases (ESBLs) belonging to the Ambler class A group 
have also been described for A. baumannii. Assessment of their true prevalence is 
hindered by difficulties with laboratory detection, especially in the presence of an 
AmpC. Recently more focus has been placed on VEB-1,(VEB-1a) ; PER-1,  and PER-
2 . Other ESBLs identified in A. baumannii include TEM-92, TEM-116  and SHV-12 
(51) as well as CTX-M-2 and CTX-M-43. Narrow-spectrum β-lactamases such as 
TEM-1 and TEM-2, are also prevalent in A. baumannii, but their current clinical 
significance is limited given the potency of other resistance determinants (51).
Treatment 
A baumannii is intrinsically multidrug resistant. Relatively few antibiotics are active 
against this organism. While colonization should not be treated, infections with this 
organism should be treated. Antibiotics to which Acinetobacter is usually sensitive 
include meropenem, colistin, polymyxin B, amikacin, rifampin and tigecycline. First, 
second and third-generation cephalosporins, macrolides, and penicillins have little or 
no anti-Acinetobacter activity. Their use may predispose to Acinetobacter 
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colonization. Although meropenem was the drug of choice to treat infections caused 
by A. baumannii, resistant strains to carbapenems have been encountered. Therefore, 
older polymyxin antibiotics such as colistin, polymyxin E and polymyxin B   have 
been evaluated. Polymyxins were discovered and isolated from Bacillus polymyxa in 
1947. The polymyxin structure consists of a fatty-acid side chain attached to a 
polycationic-peptide ring made up of 8 to 10 amino acids, allowing polymyxins to be 
amphipathic, permitting them to be water (or blood) soluble as well as in the lipid 
bilayer present in prokaryotic and eukaryotic cell membranes (Figure 9).
Figure 9. Structure of Colistin backbone
 The mechanism of action of Polymyxins is unique in that it causes disruptive 
physiochemical effects on the cell membrane and it is not susceptible to changes in 
the organism’s metabolic activity. This mechanism is achieved by displacing the 
organism’s calcium and magnesium bridges that stabilize the lipopolysaccharide 
(LPS) molecules. This destabilization causes a negative charge on the LPS, resulting 
in a more permeable membrane and allowing the leakage of bacterial contents. In 
addition, polymyxins have potent antiendotoxin activity, allowing them to avoid 
neutralization by the gram negative bacteria. Polymyxins are known to be 
bacteriostatic at low concentrations and bactericidal at high concentrations. 
24
Nephrotoxicity and neurotoxicity have been the cause of polymyxins’ notoriety and 
decreased use in treating infections (52). 
 However, newer agents are now available that may add to the treatment 
armamentarium against MDR. Tigecycline (Figure 10) is a relatively new FDA-
approved antimicrobial agent used to treat poly-microbial infections in complicated 
skin and intra-abdominal infections. It may also be used in cases where deep tissue 
penetration is needed, or where multi-drug resistant pathogens are suspected. 
Tigecycline has good in vitro activity against imipenem-resistant pathogens showing 
100% sensitivity.
Figure 10. Structure of Tigecyclin backbone
Prevention
Isolation: Patient-isolation precautions are designed to prevent transmission of 
microorganisms by common routes in hospitals. Because agent and host factors are 
more difficult to control, interruption of the spread of microorganisms is directed 
primarily at transmission.
Handwashing: Handwashing is frequently called the single most important measure 
to reduce the risks of transmitting microorganisms from one person to another or from 
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one site to another on the same patient. Washing hands as promptly and thoroughly as 
possible between patient contacts and after contact with blood, body fluids, secretions, 
excretions, and contaminated equipment or articles is an important component of 
infection control and isolation precautions. Although handwashing may seem like a 
simple procedure, it is often performed incorrectly. Healthcare settings must 
continually remind practitioners and visitors on the proper procedure in washing their 
hands to comply with effective hand-washing practices.
Visitors: In order to adequately control the spread of infections, all visitors must 
follow the same precautionary measures as hospital staff. Visitors and healthcare 
personnel are equally to blame in transmitting infections. Moreover, multi-drug 
resistant infections can leave the hospital and become part of the community flora if 
the necessary steps are not taken in consideration to curb their transmission. 
Gloves: In addition to handwashing, gloves play an important role in reducing the 
risks of transmission of microorganisms. Gloves provide a protective barrier and 
prevent gross contamination of the hands when touching blood, body fluids, 
secretions, excretions, mucous membranes and skin. They can reduce the chance that 
microorganisms present on the hands of the medical staff will be transmitted to 
patients during invasive or other patient-care procedures that involve touching a 
patient's mucous membranes and nonintact skin. Gloves can also reduce the chance of 
cross contamination between the medical staff and patients. Gloves must be changed 
between patient’s contacts and hands must be washed after their removal. Gloves does 
not replace the need for handwashing, they may have small, non-apparent pores where 
hands can become contaminated. Failure to change gloves between patient contacts is 
an infection control hazard.
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Aprons: Wearing an apron during patient care reduces the risk of infection. The apron 
should either be disposable or be used only when caring for a specific patient under 
specific circumstances.
Aims of the study:
Acinetobacter baumannii has emerged as a major nosocomial pathogen. Meropenem 
and imipenem are the most commonly used antimicrobials to treat infections inflicted 
by  this  pathogen.  Recently,  resistance  mechanisms  have  evolved  causing  this 
microorganism to become resistant to these antibiotics. Our aims of this study were:
• To determine the antimicrobial susceptibility of Acinetobacter baumannii 
isolates.
• To determine the minimum inhibitory concentration of A. baumannii 
isolates to meropenem, ciproxin and colistin individually and meropenem 
and ciproxin in combination using the agar dilution method. 
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• To evaluate the resistance of this organism to fluoroquinolones by PCR. 
Mutations on the gyrA and parC genes will be determined.
• To evaluate the presence of carbapenemase resistant genotypes by PCR. 
The presence of the oxacillinase genes OXA-23, OXA-24, OXA-51 and 
OXA-58 will be determined. 
Materials and Methods
Specimens collection: 
Eighty five clinical isolates of A. baumannii were recovered from inpatients at 
Makassed Islamic Hospital in Jerusalem from January to December in the year 2007. 
The isolates were stored at -20oC containing glycerol (10%) before the start of this 
study. The BBL-crystal Enteric/Nonfermentor system (Becton, Dickinson and 
company, Boston) was used to identify all isolates. The isolates were collected from 
different wards in the hospital: 22 (26%) isolates from neonate intensive care unit, 12 
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(14%) from surgical ward, 11 (13%) from orthopedic ward, 9 (10.5%) from medical 
ward, 9 (10.5%) from pediatric intensive care unit, 8 (9.4%) from adult intensive care 
unit, 6 (7%) from pediatric ward, 4 (4.7%) from open heart ward, 1 (1.2%) from 
cardiac care unit, 1 (1.2%)from maternal ward and 2 (2.3%) from emergency. The 
total outcome of 52% of the isolates was from intensive care units (Fig 11). The 
isolated were collected from different sources: Blood, wounds, sputum, urine, nasal, 
eyes, rectal and catheters. 
Figure 11: Distribution of A. baumannii isolates according to hospital wards at 
Makassed Charitable Hospital.
NICU: Neonate intensive care unit, SW: Surgical ward, OW: orthopedic ward, MW: Medical ward, PICU: 
Pediatric intensive care unit. AICU: Adult intensive care unit, PW: Pediatric ward, OH-ICU: Open heart-intensive 
care unit, CCU: cardiac care unit, GYN: Gynecology ward, ER: Emergency room.
Antimicrobial Susceptibility Testing:
MICs for meropenem (Dy223, AstraZeneca UK limited) and ciproxin (CRP5641203 
Birzeit Pharmaceutical company) were individually determined by agar dilution 
according to Clinical Laboratory Standard Institute (CLSI) using 0.5 McFarland 
inoculum and the Steers-Replicator (Figure 2).  This allowed the testing of a total of 
37 microorganisms simultaneously on a single agar plate (Figure 12). Antibiotic-
29
standard powders of meropenem with potency of 74% and ciproxin with potency of 
99.8% were used. The concentrations tested for meropenem were: 0.5. 1, 2, 4, 8, 16, 
32, 64, 128 and 246 μg/ml and for ciproxin were: 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64 and 
128 μg/ml. The checkerboard panel method was used for the MIC determination of 
meropenem/ciproxin combinations (Table 1). The interpretation of the antimicrobial 
combinations was done by reading the first clear spot as shown in Figure 12 in each 
row of the panel with both agents. Based on this reading, Fractional Inhibitory 
Concentrations (FICs) were calculated for each antimicrobial alone and in 
combination. The following formulas were used to calculate the FIC: 
FIC of meropenem=MIC of meropenem in combination/MIC of meropenem alone. 
FIC of ciproxin=MIC of ciproxin in combination/MIC of ciproxin alone. 
FIC Index (∑FIC) = FIC of meropenem + FIC of ciproxin. 
FIC index results for each combination were interpreted as: 
Synergy:  if the decrease in the MIC of each agent was ≥4-fold (∑FIC ≤ 0.5).
Partial synergy: if the decrease in the MIC of one agent was ≥4-fold and the decrease 
in the MIC of the other agent was 2-fold (∑FIC > 0.5 and <1).
Additive:  if the decrease in the MIC of both agents was 2-fold (∑FIC = 1). 
Indifference: if the interactions did not meet the above criteria and were not 
antagonistic (∑FIC >1 and <4).
Antagonism:  if an increase in the MIC of both agents was ≥4-fold (∑FIC ≥ 4). 
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Figure 12. Representative plates for antimicrobial susceptibility by the agar dilution 
method using Steer’s replicator (not sequential).
Cip/Mer Antibiotic Combination
µg/ml 128 64 32 16 8 4 2 1
64 64/128 64/64 64/32 64/16 64/8 64/4 64/2 64/1
32 32/128 32/64 32/32 32/16 32/8 32/4 32/2 32/1
16 16/128 16/64 16/32 16/16 16/8 16/4 16/2 16/1
8 8/128 8/64 8/32 8/16 8/8 8/4 8/2 8/1
4 4/128 4/64 4/32 4/16 4/8 4/4 4/2 4/1
2 2/128 2/64 2/32 2/16 2/8 2/4 2/2 2/1
1 1/128 1/64 1/32 1/16 1/8 1/4 1/2 1/1
0.5 0.5/128 0.5/64 05/32 0.5/16 0.5/8 0.5/4 0.5/2 0.5/1
Table 1: Checkerboard used to test combination of meropenem and ciproxin.
Rows: meropenem, Columns: Ciproxin.
In addition, the MIC of colistin sulfate (C4461 SIGMA) was determined using the 
same procedure as above, the potency of colistin sulfate powder was 99.8%. The 
concentrations tested for colistin were: 0.25, 0.5. 1, 2, 4, 8 and 16 μg/ml.
PCR Amplification, DNA Sequencing, and Restriction Endonuclease 
Digestion
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Extraction of DNA for PCR: 
Isolates were grown overnight on BAP at 37oC. Five to ten colonies of each isolate 
were removed with a sterile loop and emulsified in 100 µl of sterile distilled water in 
a 0.2 ml Eppendorf tube. Lyses was achieved by heating the tube for 10 minutes at 
95oC in a water bath. The tube was then centrifuged at 13,000  rpms (4).    
Amplification was then performed with 5 μl of the supernatant as the DNA template 
in 25 μl reaction volume. The complete mix consisted of the following components: 
12.5μl Go Taq Green Master Mix, 2X (Promega), 0.3 μl  upstream primer (0.1μM), 
0.3 μl  downstream primer (0.1μM), and 6.9μl nuclease free water All primers used 
for PCR amplification are listed in Table 2.
The amplification conditions were as follows: an initial denaturation step at 95o C, for 
5 minutes, 30 cycles of: 94o C for 40 seconds, annealing for 40 seconds at primer set 
specific temperature (Table 2) and extension at 72o C for 40 seconds. This was 
followed by a final extension step at 72o C for 10 minutes. A negative control of 
sterile distilled water was included with every PCR. Positive controls used were 
selected from strains tested in this project. A 100-bp DNA ladder (Thermo) was used 
to assess the size of PCR products. PCR products were resolved on 2.0 % agarose 
gels, stained with ethidium bromide and visualized on UV transilluminator, and 
selected gels were photographed. 
Digestion of parC and gyrA PCR products were performed as follows 10μl of the 
PCR products were incubated for 1 hour with 1μl HinfI ( TAKARA) , 2μl of 10X H- 
buffer and 7μl sterilized distilled water . The digestion products were separated by 
electrophoresis in 2% agarose gel.
Representative PCR products for some isolates were purified and sequenced at 
Bethlehem University for the oxallinase genes. Also representative PCR products of 
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gyrA and parC genes were selected according to their MICs and the results of RFLP 
were sequenced at Bethlehem University. The sequences obtained were read using 
Chromas version 2.33 software and were analyzed by the blast online search facility 
at http:/www.ncbi.com and www.srs.ebi.ac.uk.
Primer 
Name
Sequence 5’ to 3’ Annealing 
Tem. (oC)
Target gene Manufacturer
gyrA-F AAATCTGCCCGTGTCGTTGGT 55 gyrA-QRDR Syntezza
gyrA-R GCCATACCTACGGCGATACC 55 gyrA-QRDR Syntezza
ParC-F AAAAATCAGCGCGTACAGTG 53 parC-QRDR invitrogen
ParC-R CGAGAGTTTGGCTTCGGTAT 53 parC-QRDR invitrogen
Oxa51-F TAATGCTTTGATCGGCCTTG 52 blaOXA-51 invitrogen
Oxa51-R TGGATTGCACTTCATCTTGG 52 blaOXA-51 invitrogen
Oxa58-F AAGTATTGGGGCTTGTGCTG 50 blaOXA-58 invitrogen
Oxa58-R CCCCTCTGCGCTCTACATAC 50 blaOXA-58 invitrogen
Oxa23-F GATCGGATTGGAGAACCAGA 50 blaOXA-23 invitrogen
Oxa23-R ATTTCTGACCGCATTTCCAT 50 blaOXA-23 invitrogen
Oxa24-F GGTTAGTTGGCCCCCTTAAA 54 blaOXA-24 invitrogen
Oxa24-R AGTTGAGCGAAAAGGGGATT 54 blaOXA-24 invitrogen
Table 2: Primers and annealing temperatures used for the amplification of genes in A. 
baumannii isolates.
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Results
Antimicrobial Susceptibility Testing
Antimicrobial susceptibility testing was performed for all bacterial strains by disc 
diffusion method following the guidelines of CLSI. Minimal inhibitory concentrations 
for A. baumannii isolates against ciproxin, imipenem and colistin were performed 
using the agar dilution method.  The results obtained are summarized in Tables 3, 4 
and 5 and Figures 13 and 14. Interpretations of the results were done according to the 
CLSI recommendations.  The MIC for ciproxin was considered sensitive at ≤1 ug/ml, 
intermediate at 2 ug/ml and resistant at ≥4 ug/ml as shown in Table 3. The MIC for 
meropenem was considered sensitive at ≤4 ug/ml, intermediate at 8 ug/ml and 
resistant at ≥16 ug/ml as shown in Table 4. At present, there is no agreement on how 
to interpret resistance for colistin. The Société Française de Microbiologie uses a cut 
off of 2.0 mg/l, whereas the British Society for Antimicrobial Chemotherapy sets a 
cutoff of 4.0 mg/l or less as sensitive, and 8 mg/ml or more as resistant as shown in 
Table 5. So far, there are no current US standards for interpreting susceptibility for 
colistin. 
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There results obtained revealed that 86% (73/85) of the isolates were resistant to 
ciproxin, and 14% (12/85) were susceptible and none were intermediate as shown in 
Figure 13.
Table3.  A. baumannii (n=85) MIC ranges and distributions for ciproxin by agar 
dilution. (S: sensitive, I: intermediate, R: resistant). 
 
MIC μg/ ml for ciproxin     
0.25 0.5 1.0 2.0 4.0 8.0 16 32 64 128 Total
N 10 0 2 0 18 24 5 5 12 9 85
% 11.8 0 2.4 0 21.2 28.2 5.9 5.9 14.1 10.6 100%
Interpretation S S S I R R R R R R
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Figure 13. Percent susceptibility of A. baumannii to ciproxin.
There were 65.9% (56/85) of the isolates resistant to meropenem, 3.5% (3/85) 
intermediate and 30.6% (26/85) susceptible as shown in Figure 14 
  Table 4   A. baumannii (n=85) MIC ranges and distributions for meropenem by agar 
  dilution. 
  S: sensitive, I: intermediate, R: resistant
MIC μg/ ml for Meropenem   
0.5 1.0 2.0 4.0 8.0 16 32 64 128 265 Total
N 10 8 8 0 3 2 2 5 41 6 85
% 11.8 9.4 9.4 0 3.5 2.4 2.4 7.1 48 7.1 100%
Interpretation S S S S I R R R R R
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 Figure 14. Percent susceptibility of A. baumannii to meropenem.
S: Sensitive, I: intermediate, R: resistant
For colistin, 100% (85/85) or all isolates were susceptible as shown in Table 5
                                          MIC μg/ ml for Colistin sulfate       
   0.25  0.5 1.0   2.0   4.0  Total
N    6   71   6   2    0   85
%    7.1   83.5   7.1   2.3    0   100%
Interpretation    S   S   S    S    R
Table 5.  A. baumannii (n=85) MIC ranges and distributions for colistin sulfate by 
agar dilution. (S: sensitive, I: intermediate, R: resistant).
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 The MIC50 and MIC90 were determined for each of the three antibiotics tested as 
shown in Table6 and compared as shown in Figure 15. 
    Meropenem        Ciproxin  Colistin sulfate
MIC50 (μg/ml)         128         8           0.5
MIC90 (μg/ml)          128         64           0.5    
     S %          30.6         14.1            100
     I %          3.5          0            0
     R %         65.9          85.9            0
Table 6.   A. baumannii isolates susceptibility to Meropenem. Ciproxin and Colistin 
sulfate (MIC50, MIC90,sensitive, intermediate and resistant percentages).
Susceptiiblity of A. baumannii to ciproxin, meropenem 
and colistin
0
40
80
120
160
MIC50
(μg/ml)
MIC90
(μg/ml) 
     S %      I %      R %
M
IC
    Meropenem        Ciproxin  Colistin sulfate
Figure 15. Comparison of the antimicrobial susceptibility of A. baumannii to ciproxin, 
meropenem and colistin.
Note: MIC50 and MIC90 for colistin are not apparent in this figure because their values were 0.5 ug/ml
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Synergy testing
The presence of synergy between meropenem and ciproxin was evaluated using 
different combinations of the two antibiotics by the agar dilution method. The 
outcome of this experiment is shown in Table 7 and Figure 16, delineating the 
percentage of isolates with synergistic, partially synergistic, additive, indifferent, or 
antagonistic combinations for meropenem and ciproxin. The MIC ranges of the 
different strains to different combinations of  meropenem and ciproxin are shown in 
Tables 8 and 9 . 
Examples of calculating the combination outcomes of the two tested antibiotics 
(ciproxin and meropenem) are stated as follows:
Antagonism:
 Isolate 75 had MIC of 0.25 μ/ml (sensitive) for ciproxin and 0.5 μ/ml ( sensitive) for 
meropenem. The combination of both drugs was antagonistic with ciproxin at 
0.5 μg/ml and meropenem at 2 μg/ml (∑FIC = 6)
Synergy:
Isolate 60  had MIC of 64 μg/ml (resistant) for ciproxin and 32 μg/ml ( resistant) for 
meropenem. The combination of both drugs was synergistic with ciproxin at 
8 μg/ml and meropenem at 4 μg/ml (∑FIC = 0.25)
Partial Synergy:
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Isolate 39 had MIC of 4 μg/ml (resistant) for ciproxin and 64 μg/ml ( resistant) for 
meropenem. The combination of both drugs was partial synergy with ciproxin at 
0.5 μg/ml and meropenem at 32 μg/ml (∑FIC = 0.5).
Indifference:
Isolate 47 had MIC of 1 μg/ml (sensitive) for ciproxin and 32 μg/ml (resistant) for 
meropenem. The combination of both drugs was indefference with ciproxin at 
0.5 μg/ml and meropenem at 32 μg/ml (∑FIC = 1.5).
Additive:
Isolate 69 had MIC of 4 μg /ml (resistant) for ciproxin and 128 μg /ml ( resistant) for 
meropenem. The combination of both drugs was additive with ciproxin at 
2 μg/ml and meropenem at 64 μg /ml (∑FIC = 1).
Outcome
n %
 
     Synergy 8 9.5
  
     Partial synergy 44 52
    
     Additive 1 1.2
    
     Indifference 19 22.6
   
     Antagonism 12 14.3
     
       Total 85 100
Table7. Frequency (%) of combination outcomes (synergy, partial synergy, additive, 
indifference and antagonism) for all clinical isolates (n=85) of A. baumannii. 
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Figure16. Frequency percentage of A. baumannii isolates demonstrating antimicrobial 
susceptibilities in combinations of ciproxin and meropenem.
  Meropenem MIC (μg/ml)
Outcome ≤ 2 ( n =26 ) ≥ 4 and ≤ 8 (n =3 ) ≥ 16 ( n=56 )
Synergy 0 1 7
Partial synergy 0 2 43
Additive 0 0 1
Indifference 14 0 0
Antagonism 12 0 0
Table8. A. baumannii synergy testing results as a function of meropenem MIC
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  Ciproxin MIC (μg/ml)
Outcome ≤ 2 ( n =12 ) ≥ 4 and ≤ 8 (n =42) ≥ 16 ( n=31 )
Synergy 0 2 5
Partial synergy 0 37 8
Additive 0 1 0
Indifference 1 2 16
Antagonism 11 0 2
Table9.  A. baumannii synergy testing results as a function of ciproxin MIC
PCR amplification for carbapenemases
PCR amplification and subsequent agarose gel electrophoresis of class D β-lactamase 
genes revealed that 100% of the isolates contained OXA-51 genes. The size of OXA-
51 DNA gene fragment was found to be 353 bp. As shown in Table10, only two 
isolates contained OXA-58 gene fragment, its size was found to be 599 bp, and two 
isolates contained OXA-23 gene fragment of 501 bp.  The majority of the isolates 
(63/85) carried the OXA-24 gene fragment of 246 bp (Figure 19). Only one isolate 
contained both OXA-58 and OXA-24 genes. These resistant genes were not detected 
in 19 isolates. Two of these isolates (2/19) were resistant to meropenem while the rest 
(17/19) were sensitive to this drug. The distribution of oxacillinases in A. baumannii 
susceptible and resistant to meropenem is shown in Figures 17 and 18.
42
MIC 
Meropenem
   OXA-51       OXA-58     OXA-23       OXA-24
0.5 10 0 0 5
1.0 8 0 0 4
2.0 8 0 0 0
4.0 0 0 0 0
8.0 3 0 0 2
16 2 1 0 1
32 2 0 1 0
64 5 0 1 4
128 41 1 0 41
256 6 0 0 6
Table10. Number of isolates detected carrying carbapenemases genes
       Figure 17. Class D beta lactamase (oxacillinase) expression in A. baumannii  
       resistant to meropenem, 59 resistant and intermediate isolates.
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          Figure18. Class D expression in A. baumannii susceptible to meropenem, 26  
          isolates.
M 1 2 3 4
     
599
501
353
246
44
Figure19. Representative gel showing the PCR products for the 
different oxacillinase genes. Lane M: 100 bp ladder, Lane1: oxa58, 
lane 2: oxa23, lane 3: oxa-51, lane 4: oxa24.
      
                
M 1 2 3 4 5
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Figure 20. Representative gel showing the PCR products for Oxa-24. 
Lane M; 100-bp ladder, lanes 1,2, 4 and 5: resistant A. baumannii 
isolates to meropenem. Lane3: meropenem susceptible A. baumannii 
isolate (heteroresistant)
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Figure 21. Detection of heteroresistant A. baumannii for meropenem. Heteroresistant 
colonies are located inside the susceptibility zones of imipenem and meropenem at the 
head of the arrow.
PCR amplification of QRDR of ParC and gyrA3
The PCR product had the expected size of 343 bp for gyrA gene fragment and 197 bp 
for ParC gene fragment. After digestion with Hinf1 restriction enzyme those 
fragments which are carrying a mutation resulting in no digestion of fragment while 
those which are not carrying a mutation in QRDR generated two fragments of 144 and 
53 bp for ParC ( Figure 23) fragment and 291 and 52 bp for gyrA (Figure 24). The 
correlation between the levels of MIC and mutations in the QRDR region is shown in 
Table 11 and Figure 22.
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MIC
 μg /ml
N ParC 
mutated
ParC
Nonmutated
GyrA
mutated
GyrA
nonmutated
0.25≥MIC<2 12 0 12 0 12
2≥MIC<4 18 0 18 18 0
4≥MIC<32 34 0 34 34 0
32≥MIC≤128 21 21 0 21 0
Sum 85 21 64 73 12
Table11. Number of mutated isolates (uncut when digested with HinfI) and 
nonmutated ones (cut into 2 fragments when digested with HinfI) 
Figure 22. Correlation of mutations in the gyrA and parC according to individual 
MICs obtained for A. baumannii isolates.
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M 1 2 3 4 5
Figure 23. Representative gel for parC gene. Lane M: 100 bp ladder. 
Lane1: undigested PCR product. Lane2: A. baumannii susceptible to 
ciproxin and digested with HinfI (Cut). Lane 3: A. baumannii resistant 
to ciproxin (MIC=16) and digested with HinfI (Cut). Lane4: A. 
baumannii resistant to ciproxin (MIC=32) and digested with HinfI 
(uncut). Lane5: A. baumannii resistant to ciproxin (MIC=128) and 
digested with HinfI (uncut). 
197
144
53
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M 1 2 3 4 5 6 7
Figure 24: Representative gel for gyrA products of A. baumannii. Lane 
M: 100 bp ladder. Lane1: undigested PCR product.  Lanes 2, 3, 4, 5, 6 
and 7: digested PCR products by HinfI with MICs of 0.5, 4, 8, 32, 64 
and 128 respectively. Lane 2: susceptible (Cut). Lane 3,4,5,6 and 7 
resistant (uncut).  
The sequencing of representative PCR products of gyrA gene revealed that there was 
a mutation in codon 83 in which the serine was substituted to leucine in those ≥ 2 
μg/ml ( Intermediate and resistant ) while those which were sensitive showed no 
mutation. No results were obtained for mutation in parC gene in analyzing the 
sequences.
DISCUSSION
343
291
52
50
 
A. baumannii is an important causative agent of nosocomial infections. In many cases, 
carbapenems have proved to be the drug of choice in treating these infections; 
however, a number of reports worldwide highlighted the occurrence of multidrug-
resistant A. baumannii including carbapenem. Combinations of agents that exhibit 
synergy or even partial synergy could be an option to improve the treatment of 
patients with infections caused by resistant A. baumannii. In this study, meropenem 
resistance was seen in 69.4% (59/85) of the isolates and 85.9% (73/85) were resistant 
to ciproxin. The checkerboard method used to check combinations of antibiotics 
revealed that meropenem and ciproxin were synergistic in 9.5% (8/85), partially 
synergistic in 52% (44/85), additive in 1.2% ( 1/85), indifferent in 22.6% (19/85), 
and antagonistic in 14.3 (12/85). Thus synergism and partial synergism could be 
apparent in the majority of isolates, particularly in those with elevated meropenem 
and ciproxin MICs (≥ 16 μg/ml). Our results revealed the presence of synergy in cases 
where elevated MICs for both antibiotics ( ≥ 32 μg/ml ), while partial synergy was 
seen in cases where one of the two antibiotics was elevated  ≥ 32μg/ml and the other 
resistant with MICs ≥ 4μg/ml and ≤ 32μg/ml . Indifference was observed in 
susceptible or intermediate to one of the two antibiotics and resistant to the other with 
elevated MICs.  Antagonism was seen in all isolates susceptible to both antibiotics 
with MICs ≤ 2 μg/ml.  Additive reaction was seen in only one isolate that was 
resistant to meropenem with MIC of 128 μg/ml and 4 μg/ml for ciproxin.
There is a wealth of literature investigating antimicrobial combinations for A. 
baumanii. In one study, combinations of imipenem and amikacin, ampicllin/sulbactam 
and amikacin revealed that 100% (14/14) and 92.9% (13/14) of isolates respectively 
were synergistic or partialy synergistic. (53). Another study performed on 
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combination of meropenem and sulbactam for 48 isolates collected from Brazilian 
hospitals revealed that were 77.1% (37/48) isolates were synergistic and partially 
synergistic (54). Five strains of MDR A. baumannii tested in a study conducted in 
London on combinations of polymyxin B with imipenem, azythromycin and 
rifampicin using Etest, (55) did not show marked synergy. The study supported that 
drug combination is an important aspect in optimization of therapy. Moreover, the 
drug combination meropenem and ciproxin revealed synergy and partial synergy of 
61%, it can be used as guide to clinical efficacy where appropriate therapies should be 
further investigated.
Recently, A. baumannii is implicated in frequent nosocomial infections. Therefore it is 
important to investigate the relationship between genotyping and drug resistance of 
strains isolated during epidemics or outbreaks in hospitals. One of the important goals 
of this study was to correlate resistance phenotypes and the genetic determinants of 
resistance in A. baumannii for meropenem and ciproxin. Resistance to meropenem 
was seen in 69.4% of all isolates. Expression of class D beta-lactamases revealed that 
OXA-51 was present in all isolates, OXA-24 genes were expressed in 92.4% of the 
resistant isolates, OXA-23 genes were expressed in only two isolates, 3.4%, and two 
isolates expressed OXA-58 genes, 3.4%. Only one of the 59 isolates resistant to 
meropenem expressed both genes OXA-58 and OXA-24. Two meropenem-resistant 
isolates did not express any of the three oxacillinase genes investigated in this study, 
OXA-23, OXA-24 or OXA-58, indicating that the mechanism of resistance for these 
isolates were undefined subgroups of OXA enzymes, or alternative mechanisms of 
resistance. There were 30.6% of isolates susceptible to meropenem. All of these 
isolates expressed the OXA-51 genes, 36.4% of them expressed the OXA-24 genes as 
shown in Figure 20(the bands were not sharp).  
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The expression of the OXA-24 genes in these 9 meropenem-susceptible isolates can 
be explained by two concepts: a mutation on the OXA-24 gene (encoding the 
carbapenemase) caused the gene to be silent; evolution of heteroresistance: 
(subpopulations of genetically identical subclones that are more resistant than the 
original parent) may explain the second concept.  In this study, the evolution of 
heteroresistance was investigated. Heavy suspension (2 McFarland) of each of the 9 
isolates was spread onto Mueller Hinton plates and meropenem and imipenem discs 
were added, the plates were incubated overnight in a non-CO2 incubator at 37o C. The 
detection of small number of colonies within the susceptible zone indicates 
heteroresistance as shown in Figure 21 . Some of these colonies were taken and 
streaked on BAP to confirm that the correct identity of the colonies as A. baumannii 
and the PCR was repeated to confirm the presence of OXA-24 gene. The results 
obtained from this experiment proved that isolates tested were true heteroresistant 
strains. 
These results warrant that A. baumannii susceptible to meropenem with routine 
procedures must be confirmed by additional screening methods to detect 
heteroresistance. This is extremely important for clinicians and physicians to prevent 
selection pressure for resistance.
A study in USA, on isolates recovered from Military and civilian patients treated at 
the Walter Reed Army Medical Center, OXA-23 and OXA-58 like carbapenemase 
genes were found in 90% of the meropenem resistant isolates, whereas OXA-69 (from 
the same cluster of OXA-51) was detected in 97% of isolates which were susceptible 
and resistant to meropenem (56).
In another study done in southern Europe, the Balkan, and central Turkey, 22 out of 
42 isolated were positive to OXA-58 gene and 2 isolates for OXA-23 and 10 isolates 
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had OXA-40 (from the same cluster of OXA-24) (32),  while OXA-40 was 
disseminated in Portugal (33).
A study was done on 30 carbapenem nonsusceptible  Acinetobacter spp isolates 
collected in Argentina, Kuwait and Britain had revealed the occurrence of OXA-51 
gene in 28/30 isolates and 30/30 had OXA-58 (34). 
The OXA alleles encoding known carbapenemases were studied in 250 isolates of 
Acinetobacter spp. from the UK and the results obtained were 232/250 had OXA-51 
gene, 154/250 isolates had OXA-23 gene, 20/250 isolates had OXA-58 gene while 
OXA-24 was not detected in any isolate (57).
Comparing our study with the previous studies, OXA-51 genes were detected in all 
isolates irrespective of the levels of carbapenem susceptibility, consistent with the 
view that they are intrinsic to A. baumannii. Therefore, the presence of this intrinsic 
gene does not correlate with the level of carbapenem resistance of the isolate. 
Although OXA-24 was not detected in the UK isolates, it was prevalent in the isolates 
tested in this study. The occurrence of OXA-58 gene was verified in strains tested in 
the three continents, our study indicated that this gene occurs in Palestine as well. 
According to the antimicrobial susceptibility tests conducted in this project, 86% of 
isolates were resistant to ciproxin. All isolates carry the gyrA and parC genes in the 
QRDR.  Resistance to quinolones can be due to mutations in these genes. In this 
study, PCR products for gyrA (343 bp) and parC (197 bp) were digested with HinfI 
restriction enzyme. The restriction site for HinfI on the gyrA gene is located at codon 
83 and at codon 80 on the parC gene. Mutations at codon 83 and 80 in these 
respective genes (gyrA and parC) will result in non-digestion at these sites giving the 
full length PCR product.  On the other hand, non-mutated genes will be restricted by 
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the HinfI enzyme giving two fragments of 291 and 52 bps for gyrA and 144 and 53 
bps for parC genes. 
Our results indicated the presence of correlation between resistance to ciproxin and 
mutations at gyrA. It was found in this study that isolates with MIC ≥2 μg/ml was not 
digested with the restriction enzyme, proving to be mutated at codon 83. Isolates with 
MICs ≤ 1 μg/ml were digested into two fragments indication no mutations in the gyrA 
gene. The results obtained by restriction with HinfI were verified by sequencing. The 
results obtained by sequencing revealed the presence of substitution of serine to 
leucine at codon 83.  
For parC, MICs for ciproxin of ≤ 32 μg/ml in all isolates, our results revealed the 
absence of mutations. Therefore, the presence of mutations in the parC gene must 
coincide with mutations in the gyrA gene. The essence of our results suggests that 
parC gene from A .baumannii is a secondary target for quinolones and that mutation 
at codon 80 of parC when combined with mutation at codon 83 of gyrA, may render 
A. baumannii highly resistant to quinolones.  It is apparent that our results are in 
agreement with other studies done worldwide.  In one study,  147 isolates of 
A.baumannii were collected from various hospitals in Europe and USA, all quinolone 
resistant isolates showed mutations at codon 83 of gyrA gene while those MIC ≥ 32 
μg/ml showed mutations at codon 80 and 84 of parC gene.(45). A similar study was 
done on isolates from three Spanish hospitals, revealed the same forementioned 
results.(58). A previous study conduced in Spain in 1995, similar results were 
obtained in addition to mutations in the gyrA gene at codons 81 and 84 (44). 
In this study as well as other studies, only small regions of the gyrA and parC genes 
were examined. It is possible that mutations at other locations or in other genes may 
contribute to ciproxin resistance in A. baumannii. 
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Sequencing of the parC gene products did not reveal the presence of mutations. It was 
apparent in our results obtained by the RFLP test that these mutations existed. This 
controversy can be explained by examining the flanking regions of the parC gene 
products. The mutations may be found in these regions or juxtaposition to it. The 
sequences obtained in the flanking regions were not clear enough to draw a definite 
conclusion in this aspect. Therefore, in order to determine the presence of mutations 
in the flanking regions of the parC gene products, new experiments must be designed 
using primers that will amplify this region. 
Recommendations
• To establish a functional National and Hospital Infection Control Committee
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• The combination of antibiotics conducted in-vitro must be confirmed by in-
vivo studies.
• Combinations should be performed by using broth dilution or agar dilution 
methods.
• Synergy and partial synergy results can be used as a guide to the efficacy of 
both antibiotics tested where further therapies should be investigated. 
• Strict rules must be implemented in hospitals to curb the spread of MDR A. 
baumannii.
• Further studies should be conducted by PFGE to determine the relatedness of 
the strains and their correlation with the resistance genotypes 
• Any A. baumannii isolate susceptible to carbapenems must be retested using 
heavy inoculum (2 McFarland) to rule out the presence of heteroresistance to 
prevent selection pressure.
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